![](https://insights.axtria.com/hubfs/Everest%20Group%20Life%20Sciences%20Digital%20Services%20Specialists.png)
Trending
Everest Group Life Sciences Digital Services Specialists PEAK Matrix® Assessment 2024
We’re proud to have been named a Leader in the Everest Group Life Sciences Digital Services Specialists PEAK Matrix® Report. Everest Group classified ...
![From Chaos to Cohesion](https://insights.axtria.com/hs-fs/hubfs/From%20Chaos%20to%20Cohesion-1.jpg?width=234&height=327&name=From%20Chaos%20to%20Cohesion-1.jpg)
Rare Diseases
![Challenges And Opportunities To Commercialize Orphan Drugs For Rare Diseases In The US](https://insights.axtria.com/hubfs/Axtria-2023/media-wall/Betting-the-House-on-Orphan-Drugs-400x250-1.jpg)
Challenges And Opportunities To Commercialize Orphan Drugs For Rare Diseases In The US
Orphan drugs (ODs) for rare diseases (RDs) present pharma companies with the opportunity to address a substantial unmet medical need, with approximately 7,000 RDs and only about 5% having effective treatments. A large number of patients in the US are affected by these RDs (around 25-30 million people). The majority of RDs affect children. Also, RDs often translate into chronic and deteriorating ...